Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Recap: Collegium Pharmaceutical Q1 Earnings
Collegium Pharmaceutical (NASDAQ:COLL) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:01 PM. Here’s what…
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell
• Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target
Needham analyst Serge Belanger reiterates Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and maintains $35 price target.
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell
• ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell
• Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Collegium Announces 11 Poster Presentations At PAINWeek 2022 September 6-9
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentationsSTOUGHTON, Mass., Aug.
Analyst Sees This ‘Specialty Pharma’ Stock Stuck Until Prescription Trends Improve
Last week, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright…
UPDATE: Collegium Pharmaceutical Q2 Adj. EPS $0.33 Misses $1.45 Estimate, Sales $123.55M Beat $121.80M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $0.33 per share which missed the analyst consensus estimate of $1.45 by 77.24 percent. This is a 22.22 percent increase over earnings of $0.27 per
Collegium Pharmaceutical Q2 EPS $(0.15) Misses $1.45 Estimate, Sales $123.55M Beat $121.80M Estimate
Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $1.45 by 110.34 percent. This is a 155.56 percent decrease over earnings of $0.27 per